Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life a systematic review

Chest

Volumn 146, Issue 3, 2014, Pages 686-708

  Rival, Gilles ^a,b   Lacasse, Yves ^a   Martin, Sylvie ^a   Bonnet, Sébastien ^a   Provencher, Steeve ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; RIOCIGUAT; SILDENAFIL; SITAXSENTAN; TADALAFIL; TREPROSTINIL;

ADULT; ARTICLE; CHRONIC HEART FAILURE QUESTIONNAIRE; CONNECTIVE TISSUE DISEASE; EUROQOL 5D; HUMAN; LIVING WITH PULMONARY HYPERTENSION QUESTIONNAIRE; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; MONOTHERAPY; NOTTINGHAM HEALTH PROFILE; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 12; SHORT FORM 36; SYSTEMATIC REVIEW; FAMILIAL PRIMARY PULMONARY HYPERTENSION; PSYCHOLOGY; REPRODUCIBILITY; TREATMENT OUTCOME;

FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84907190841     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2634     Document Type: Article

References (70)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115 (5): 343-349.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classifi cation of pulmonary hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S43-S54.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14): 1425-36.
4. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A metaanalysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009; 30 (4): 394-403.
5. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Longterm outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27 (5): 589-595.
6. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40 (4): 780-788.
7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106 (12): 1477-1482.
8. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. E ur Respir J. 2005; 25 (2): 244-249.
9. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122 (2): 156-163.
10. Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther. 1981; 29 (1): 111-123.
11. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Updated March 2011. London, England: The Cochrane Collaboration; 2011.
12. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol. 1995; 48 (1): 9-18.
13. Barst RJ, Rubin LJ, Long WA, et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334 (5): 296-301.
14. Olschewski H, Simonneau G, Galiè N, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347 (5): 322-329.
15. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165 (6): 800-804.
16. Barst RJ, McGoon M, McLaughlin V, et al; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41 (12): 2119-2125.
17. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafi l in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004; 43 (7): 1149-1153.
18. Oudiz RJ, Schilz RJ, Barst RJ, et al; Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004; 126 (2): 420-427.
19. Barst RJ, Langleben D, Frost A, et al; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169 (4): 441-447.
20. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007; 66 (11): 1467-1472.
21. Galiè N, Olschewski H, Oudiz RJ, et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008' 117 (23): 3010-3019.
22. Simonneau G, Rubin LJ, Galiè N, et al; PACES Study Group. Addition of sildenafi l to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008; 149 (8): 521-530.
23. Pepke-Zaba J, Gilbert C, Collings L, Brown MCJ. Sildenafi l improves healthrelated quality of life in patients with pulmonary arterial hypertension. Chest. 2008; 133 (1): 183-189.
24. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a doubleblind, randomised controlled trial. Lancet. 2008; 371 (9630): 2093-2100.
25. Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafi l therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin. 2009; 25 (10): 2479-2485.
26. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010; 55 (18): 1915-1922.
27. Mychaskiw MA, Hwang LJ, Liu X, Teal S, Louie M. The effect of sitaxentan on exercise capacity, hemodynamic function, and health-related quality of life in adults with pulmonary arterial hypertension associated with connective tissue disease [abstract]. Am J Respir Crit Care Med. 2011; 183 (1):A5887.
28. Mehta S, Channick R, Delcroix M, et al. Macitentan improves health-related quality of life in pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial [abstract]. Am J Respir Crit Care Med. 2013; 187 (1): A3269.
29. Ghofrani HA, Galiè N, Grimminger F, et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369 (4): 330-340.
30. Galiè N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to Tadalafi l (PHIRST) Study Group. Tadalafi l therapy for pulmonary arterial hypertension [published correction appears in Circulation. 2011;124(10):e279]. Circulation. 2009; 119 (22): 2894-2903.
31. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafi l Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafi l citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353 (20): 2148-2157.
32. Pulido T, Adzerikho I, Channick RN, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369 (9): 809-818.
33. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med. 1989; 4 (2): 101-107.
34. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important diff erence. Control Clin Trials. 1989; 10 (4): 407-415.
35. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985; 35 (273): 185-188.
36. Rehab measures: Nottingham Health Profile. http://www.rehabmeasures. Rehabilitation Measures Database. org/Lists/RehabMeasures/DispForm. aspx?ID 5 931. Accessed June 12, 2012.
37. Rector RS, Kudo SH, Cohn JN. Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure: the Minnesota Living With Heart Failure Questionnaire. Heart Fail. 1987; 3 (Oct/Nov): 198-209.
38. Minnesota Living With Heart Failure Questionnaire. University of Minnesota website. http://www.license.umn.edu/Products/Minnesota-Living-With-Heart-Failure-Questionnaire-Z94019.aspx. Accessed June 12, 2012.
39. Solberg TK, Olsen JA, Ingebrigtsen T, Hofoss D, Nygaard OP. Health-related quality of life assessment by the EuroQol-5D can provide cost-utility data in the field of low-back surgery. Eur Spine J. 2005; 14 (10): 1000-1007.
40. EuroQol Group. EuroQol-a new facility for the measurement of healthrelated quality of life. Health Policy. 1990; 16 (3): 199-208.
41. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997; 35 (11): 1095-1108.
42. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998; 51(11): 1171-1178.
43. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30 (6): 473-483.
44. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patientreported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford). 2007; 46 (6): 999-1004.
45. Gilbert C, Brown MCJ, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important diff erence in pulmonary arterial hypertension following treatment with sildenafi l. Chest. 2009; 135 (1): 137-142.
46. Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes. 2013; 11 (1): 161.
47. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. E ur Respir J. 2006; 28 (4): 808-815.
48. Humbert M, Galie N, Ghofrani A, et al. Efficacy Of riociguat in pretreated versus treatment-naïve patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study [abstract]. Am J Respir Crit Care Med. 2013; 187 (1): A3534.
49. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patientreported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc. 2008; 5 (5): 623-630.
50. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005; 6: 92.
51. Chua R, Keogh AM, Byth K, O'Loughlin A. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J. 2006; 36 (11): 705-710.
52. Halank M, Einsle F, Lehman S, et al. Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung. 2013; 191 (4): 337-343.
53. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest. 2013; 144 (2): 522-530.
54. Zlupko M, Harhay MO, Gallop R, et al. Evaluation of disease-specific healthrelated quality of life in patients with pulmonary arterial hypertension. Respir Med. 2008; 102 (10): 1431-1438.
55. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Healthrelated quality of life in patients with pulmonary arterial hypertension. Chest. 2004; 126 (5): 1452-1459.
56. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005; 40 (2): 577-591.
57. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006; 15 (1): 103-115.
58. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(suppl 1): S97-S107.
59. Barst RJ, Langleben D, Badesch D, et al; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006; 47 (10): 2049-2056.
60. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358 (9288): 1119-1123.
61. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 (12): 896-903.
62. Galiè N, Beghetti M, Gatzoulis MA, et al; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114 (1): 48-54.
63. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012; 142 (6): 1383-1390.
64. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013; 127 (5): 624-633.
65. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013; 127 (10): 1128-1138.
66. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004; 24 (3): 353-359.
67. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174 (11): 1257-1263.
68. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafi l in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010; 31 (9): 1124-1131.
69. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012; 40 (4): 874-880.
70. Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013; 22 (6): 1161-1175.